Cui Zhao, Zhao Ming-hui
Department of Nephrology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Yi Xue Za Zhi. 2005 Apr 6;85(13):903-7.
To investigate the avidity of anti-glomerular basement membrane (GBM) antibodies and their association with clinical and pathological parameters of patients with anti-GBM disease.
Sera from 52 patients and serial samples from 11 patients with anti-GBM disease, diagnosed in our hospital in the last 11 years, were collected. Purified bovine alpha chain non-collagen 1 domains of type IV collagen [alpha(IV)NC1] was employed to exam avidity of anti-GBM antibodies using antigen-inhibition enzyme-linked immunosorbent assay (ELISA). The amount of alpha(IV)NC1 needed for 50% inhibition of antibody binding was compared between patients with different clinical and pathological manifestations.
After the sera were diluted to give the same absorbance, the amount of alpha(IV)NC1 used was different among different patients, with an average at 0.625 microg (0.02-20 microg). A significant correlation was observed between the amount of alpha(IV)NC1 used and the percentage of glomerular crescents (P = 0.001). Higher avidity of anti-GBM antibodies predicted a higher percentage of glomerular crescents (R(2) = 0.58, P = 0.000). No correlation was observed between avidity and age, gender, interval between onset and diagnosis and other clinical data. No changing avidity was observed in serial samples with time.
Affinity maturation might have been completed by the time that patients presented with anti-GBM disease. The different avidity of anti-GBM antibodies was associated with the degree of renal damage and might play a key role in the pathogenesis of anti-GBM disease.
探讨抗肾小球基底膜(GBM)抗体的亲和力及其与抗GBM病患者临床和病理参数的关系。
收集我院过去11年诊断的52例患者的血清以及11例抗GBM病患者的系列样本。采用纯化的IV型胶原牛α链非胶原1结构域[α(IV)NC1],通过抗原抑制酶联免疫吸附测定(ELISA)检测抗GBM抗体的亲和力。比较不同临床和病理表现患者50%抑制抗体结合所需的α(IV)NC1量。
将血清稀释至相同吸光度后,不同患者使用的α(IV)NC1量不同,平均为0.625微克(0.02 - 20微克)。观察到使用的α(IV)NC1量与肾小球新月体百分比之间存在显著相关性(P = 0.001)。抗GBM抗体亲和力越高,肾小球新月体百分比越高(R² = 0.58,P = 0.000)。未观察到亲和力与年龄、性别、发病至诊断间隔及其他临床数据之间的相关性。系列样本中未观察到亲和力随时间变化。
抗GBM病患者出现时亲和力成熟可能已完成。抗GBM抗体的不同亲和力与肾损伤程度相关,可能在抗GBM病的发病机制中起关键作用。